Shares of Baxter International Inc. (NYSE:BAX - Get Free Report) have been given a consensus recommendation of "Reduce" by the fourteen research firms that are covering the company, Marketbeat reports. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $23.27.
Several analysts have recently weighed in on BAX shares. Citigroup dropped their price target on shares of Baxter International from $28.00 to $27.00 and set a "neutral" rating for the company in a research note on Monday, October 5th. Zacks Research upgraded Baxter International from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Wolfe Research initiated coverage on Baxter International in a report on Tuesday, October 20th. They issued a "peer perform" rating on the stock. TD Cowen increased their price objective on Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a research report on Monday, July 27th. Finally, Weiss Ratings raised Baxter International from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday, October 30th.
View Our Latest Report on Baxter International
Baxter International Stock Performance
NYSE BAX opened at $26.16 on Thursday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.19 and a current ratio of 1.79. The stock's fifty day moving average is $24.58 and its two-hundred day moving average is $21.76. The firm has a market capitalization of $13.53 billion, a P/E ratio of -18.55, a price-to-earnings-growth ratio of 3.79 and a beta of 0.68. Baxter International has a fifty-two week low of $15.73 and a fifty-two week high of $30.00.
Baxter International (NYSE:BAX - Get Free Report) last issued its earnings results on Thursday, October 29th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. Baxter International had a positive return on equity of 16.23% and a negative net margin of 6.23%. The business had revenue of $2.98 billion during the quarter, compared to the consensus estimate of $2.91 billion. During the same period last year, the company earned $0.69 EPS. The company's revenue for the quarter was up 5.0% on a year-over-year basis. On average, research analysts anticipate that Baxter International will post 2.10 earnings per share for the current year.
Baxter International Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Friday, November 27th will be paid a $0.01 dividend. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, November 27th. Baxter International's dividend payout ratio is -2.84%.
Institutional Investors Weigh In On Baxter International
A number of institutional investors and hedge funds have recently made changes to their positions in BAX. BlackRock Inc. purchased a new stake in Baxter International during the second quarter worth about $1,744,874,000. Pzena Investment Management LLC acquired a new stake in shares of Baxter International during the second quarter worth about $1,392,098,000. State Farm Mutual Automobile Insurance Co. boosted its stake in shares of Baxter International by 153.0% in the third quarter. State Farm Mutual Automobile Insurance Co. now owns 15,746,790 shares of the medical instruments supplier's stock valued at $377,923,000 after purchasing an additional 9,521,730 shares during the period. Equity Investment Corp purchased a new position in shares of Baxter International in the second quarter valued at approximately $146,815,000. Finally, Bank of America Corp DE purchased a new position in shares of Baxter International in the second quarter valued at approximately $132,993,000. 90.19% of the stock is owned by hedge funds and other institutional investors.
About Baxter International
(
Get Free Report)
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Baxter International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.
While Baxter International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.